BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » testing

Stem Cell Therapeutic & Research Act and a Critical Appraisal of Cord Blood Quality

November 24, 2015 By Cade Hildreth (CEO) Leave a Comment

Stem Cell Therapeutic and Research Act and a Critical Appraisal of Cord Blood Quality and its Consequences

Opinion Article: This is an article written by Ivan N. Rich of HemoGenix, Inc., Colorado Springs, CO, USA. It is an opinion piece that reflects views and positions of the author. It does not reflect the views of BioInformant Worldwide, LLC.

As a stem cell and cord blood industry blog, it is our role to spread discussion and allow a voice to varying opinions, perspectives, and areas of scientific expertise. If you have a reaction to this article, ask yourself, why am I reacting? How do I perceive current techniques for cord blood testing and assessment? If you have thoughts, they are encouraged in the comments section below.


November 24, 2015; HemoGenix, Inc. – The passage by voice vote of H.R. 2820, otherwise known as The Stem Cell Therapeutic and Research Reauthorization Act of 2015 through the U.S. House of Representatives [1] has been lauded by many in the cord blood community, including the Cord Blood Association (CBA) that promoted the bill. There is a good chance the Bill will become law, because health issues usually have bipartisan support. Although patients requiring a cord blood stem cell transplant have been helped by previous Bills, they have nevertheless not benefited from the principle purpose of this Bill, namely to provide high-quality cord blood stem cells for transplantation. [Read more…]

Filed Under: Cord Blood, HSCs Tagged With: Cord Blood Association, cord blood banking, hematopoietic stem cells, hemogenix, ivan rich, purity, quality, testing

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.